Thelansis

  Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by an increase in morphologically normal red cells, white cells and platelets; erythrocytosis is typical. 10% to 30% of patients eventually develop myelofibrosis and marrow failure; acute leukemia occurs spontaneously in 1.0 to 2.5%. The risk of bleeding and arterial or venous thrombosis is increased. Common manifestations include splenomegaly, microvascular events (e.g., transient ischemic attacks, ocular migraine, erythromelalgia), and aquagenic pruritus (itching triggered by exposure to hot water). Eventually, about 10 to 15% of patients progress to a syndrome compatible with primary myelofibrosis but with better survival. The incidence of diagnosed cases of Polycythemia vera (PV) is ~1.75 to 2.27 cases per 100,000 population of men and approximately 1.52 per 100,000 population of women in the USA. Polycythemia vera (PV) prevalence ranges between ~19 to 26 cases per 100,000 people....